Navigation Links
QPS Announces the Acquisition of Xendo Drug Development

NEWARK, Del. and GRONINGEN, Netherlands, July 26 /PRNewswire/ -- QPS Holdings, LLC, a leading full-service GLP/GCP-compliant contract research organization providing testing services to support preclinical and clinical research and development, announced the completion of its acquisition of Xendo Drug Development BV (XDD), headquartered in Groningen, The Netherlands.  XDD, a European contract research organization (CRO), will be known as QPS Netherlands BV and become a wholly-owned subsidiary of QPS Holdings, LLC.

(Logo: )

(Logo: )

With the completion of this acquisition, QPS further expands its global range of linearly integrated resources and services:

  • Drug discovery and development from preclinical to clinical studies for IND and NDA regulatory submissions.
  • 300 clinical pharmacology beds on three continents - 24 in the Netherlands, 24 in Taiwan and 240 in the USA - one of the world's largest phase 1 site offerings.
  • Start-up time for phase 1 clinical trials is four to six weeks, compared to several months in other European countries. Moreover, phase 2 can follow phase 1 without interruption.  Many international pharmaceutical and biotech companies have conducted first entry into man (FIM) studies in the Netherlands. This is due to Netherlands' favorable regulatory environment, streamlined protocol approval process and lower cost of managing trials.
  • One of the world's largest capacities in bioanalysis for small molecules and biologics, with global bioanalysis facilities in the USA, Europe and Asia.
  • Complete ADME package for regulatory submissions from preclinical studies to radiolabeled human mass balance (including microdosing) studies.
  • CNS drug research and development, such as Alzheimer therapy, from patient stratification, to the clinic, to in vivo imaging, to PK/PD correlation and efficacy evaluation, with clinical genotyping and specialized biomarker assay capability to support the pursuit of targeted therapies and personalized medicines..  

XDD has state-of-the-art large and small molecule bioanalytical laboratories and a dedicated 24-bed clinical pharmacology unit (CPU) located at University Medical Center Groningen (UMCG).  Established in 2004, this CPU has performed over 100 clinical pharmacology studies - many of them first entry into man (FIM) studies - across all major therapeutic areas.  This location provides comprehensive safety monitoring with 24/7 access to hospital-based crash teams and clinical specialists.  XDD also offers an extensive database of healthy volunteers as well as  special and patient populations.

"Pooling our strengths will enable XDD and QPS to serve our clients even better.  Our leading capability in conducting high quality bioanalysis and phase 1 studies, combined with our well established expertise in ADME, genotyping and drug development process will make QPS an ideal drug development partner for our pharmaceutical and biotech clients worldwide," said Ben Chien, Chairman, and CEO of QPS holdings.

"Joining the QPS organization enables XDD to realize its ambitions for global growth.  In terms of activities, size and location, QPS and XDD are a perfect fit. Our combined operations in Asia, Europe and the US position us ideally to expand our portfolios in the increasingly consolidated pharmaceutical and biotechnology sector, our primary market," said Koos Koops, XDD's former chief executive officer. Koops will head the XDD -QPS Netherlands division of QPS.

"As both QPS and XDD facilities share the same high standards and customer service philosophy, this merger will further strengthen our ability to provide our clients with quality, services, and competitive pricing worldwide," stated Ben Chien.

About Xendo

Established in 1999, XDD is a European CRO with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad range of therapeutic areas for a wide variety of clients.  XDD employs over 100 people, and provides early & late phase clinical development, data management, biometrics, medical writing, bioanalysis and resourcing solutions services.  Further information is available at

About QPS

Founded in 1995, QPS ( has bioanalysis and DMPK facilities at its Newark, DE, USA headquarters, a laboratory in Taipei, Taiwan, and phase 1 facility in Springfield, Missouri.  QPS has been providing quality services in regulated and non-regulated bioanalysis (LC/MS/MS, immunoanalytical, and hybridization-ELISA), DMPK, protein biomarkers, pharmacogenomics and pharmacogenetics markers, and phase 1 studies to its clients worldwide.

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
(Date:11/26/2015)... Research and Markets ( ) has announced the ... Type (Dressings, Therapy Devices, Active Wound Care), Application (Surgical ... Geography - Global Forecast to 2020" report to ... --> The purpose of this report is to ... advanced wound care market. It involves deep dive analysis ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... --> adds "Global ... and "Investigation Report on China Repaglinide ... 2021 forecasts data and information to ... . --> ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... of the "2016 Future Horizons and Growth ... Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> --> ... of the Italian therapeutic drug monitoring market, including ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 2015 , ... The men and women on this list ... the country. They have overseen financial turnarounds, shown commitment to their community through ... as a whole through their advocacy and professional efforts. , Becker's Hospital Review ...
(Date:11/27/2015)... San Francisco, California (PRWEB) , ... November 27, 2015 , ... ... 1969 Janis Joplin Ann Arbor Michigan boxing style concert posters. This is one of ... 1969 at the Canterbury House at the University of Michigan in Ann Arbor. The ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity Point Recovery, ... together on Thanksgiving Day to share the things that they are most grateful ... Point YouTube channel, patients displayed what they wrote on index cards, describing the ...
(Date:11/26/2015)... ON and Cambridge, ON (PRWEB) , ... November ... ... today the availability of a real-time eReferral system for diagnostic imaging in the ... ultrasounds, X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic medical ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug Delivery ... to integrate dose form selection in early phase drug development. The first of ... and bringing together the UK’s emerging life sciences companies, corporate partners, and investors, ...
Breaking Medicine News(10 mins):